2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 220-222
Transfusion medicine is rapidly evolving from the delivery of standardized blood products toward precision, data-driven therapies tailored to individual patients and clinical contexts. This session highlights cutting-edge advances spanning the continuum of transfusion care. Topics range from optimizing stem cell mobilization and red cell exchange in patients with sickle cell disease, to reducing alloimmunization through precision antigen matching, improving hemostatic management in cardiac surgery, uncovering the biological effects of platelet transfusions on the developing brain, and developing next-generation recombinant oxygen-carrying blood substitutes. Together, these presentations demonstrate how innovations in transfusion science are improving the safety, effectiveness, and sustainability of blood therapies while laying the foundation for future alternatives to donor-derived blood.
Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemoglobinopathies, Sickle Cell Disease, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

157 Predictors of stem cell collection yield in patients with sickle cell disease pursuing gene therapy.

Mauricio Barreto, MD, Julia Mewha, N/A2, David Friedman, MD3, Jarcy Zee, PhD4, Cyrus Bascon5, Julie Decaris6, Ross M. Fasano I, MD7, Reuben Paul Jacob, MD8, Mark C Walters I, MD9, Marianne Elaine McPherson Yee, MD, MSc10, Shannon Kelly, MD, PhD11, Michelle Denburg, MD, MSCE12, Stella T Chou, MD13
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
5 UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
6 UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
7 Emory University School of Medicine, Atlanta, Georgia, United States
8 Aflac Cancer and Blood Disorders Center Children’s Healthcare of Atlanta, Atlanta, Georgia, United States
9 UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
10 Aflac Cancer and Blood Disorders Center Children’s Healthcare of Atlanta, Atlanta, Georgia, United States
11 UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
12 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
13 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Introduction:

Successful stem cell mobilization and collection are essential to providing patients with sickle cell disease (SCD) access to transformative gene therapies. However, this population faces unique challenges including a contraindication to G-CSF and variable responses to CXCR4 antagonists such as plerixafor. This frequently results in the need for multiple collection cycles to obtain enough hematopoietic stem cells (HSC) for gene therapy. A period of red blood cell (RBC) transfusion prior to HSC collection appears to improve HSC yield, but the optimal HbS% goal for HSC collection remains unknown. Additionally, predictors of HSC yield are not well defined, and the transfusion burden and incidence of alloimmunization associated with current practices are sparse and single center in nature. Addressing these gaps is critical to optimize transfusion, mobilization, and collection strategies. 

Methods:

We conducted a multi-center retrospective cohort study of patients with SCD pursuing gene therapy at the Children’s Hospital of Philadelphia, UCSF Benioff Children’s Hospital Oakland, and Children’s Hospital of Atlanta. We included all patients with SCD who underwent at least one autologous HSC collection cycle for gene therapy. Our primary aim was to determine clinical and laboratory predictors of HSC yield. Information on SCD history and management, complete blood counts, HbS%, antibody tests, mobilizing agent used, and apheresis parameters were collected. We used a linear mixed effects (LME) regression model adjusted for age to determine which clinical and laboratory variables were independently associated with the primary outcome of million (e6) CD34+ cells/kg (CD34/kg) collected per apheresis procedure and collection cycle. We also analyzed the transfusion burden and incidence of alloimmunization.

Results:

Our cohort included 48 patients with SCD representing 78 collection cycles and 201 apheresis procedures. Most patients had HbSS (94%, n=45) with a median age of 20 (Range 8-33) at the time of first collection. At consent, 83% (n=40) were on hydroxyurea and 19% (n=9) were receiving chronic transfusions. Patients were transfused for a median of 83 days (IQR 59-120) prior to collection cycles to sustain lower HbS%. Plerixafor was the main mobilizing agent used for individual apheresis collections (n=178, 89%) followed by motixafortide (n=17, 8%). Median e6 CD34/kg collected was 4.8 (IQR 2.7 - 8.3) per apheresis procedure and 13.9 (IQR 7.9 - 21.1) per collection cycle.  In LME regression, every % decrease in the HbS% at the start of the collection cycle was associated with 0.5 e6 higher CD34/kg collected (CI 0.2 – 0.8, p<0.01). Patients who maintained a HbS% < 30% throughout the transfusion period preceding a collection cycle collected 2.0 e6 higher CD34/kg per cycle (CI -2.9 - 6.9, p=0.43). Each year decrease in age was associated with 0.5 e6 higher CD34/kg collected per cycle (CI 0.02 - 1.0,  p=0.04). Increasing WBC (0.18 e6 CD34/kg, CI 0.12 - 0.24) and Hgb (1.1 e6 CD34/kg, CI 0.4 - 1.8) were associated with higher CD34/kg collected per apheresis collection (p<0.01). Compared to plerixafor, patients mobilized with motixafortide had 2.9 e6 higher CD34/kg collected per apheresis procedure (CI 1.0 – 4.8, p < 0.01). History of splenectomy was associated with 2.9 e6 higher CD34/kg cells collected per procedure (CI 0.2 - 5.6, p=0.03). Patients who received gene therapy required a median of 4 (IQR 3-5) apheresis collection procedures representing a median of 2 (Range 1-4) collection cycles. Patients received a median of 60 packed RBC units (IQR 45-81). Four patients developed new alloantibodies (anti-D, -Lua, -Goa, -Jka).

Conclusion:

Among variables tested, lower HbS% immediately preceding a collection cycle was predictive of improved stem cell collection. While sustained HbS% < 30% in the regular transfusion period preceding a collection cycle showed higher yield, this was not statistically significant. This highlights the need for future studies examining HbS% targets and the optimal transfusion preparation for collection of autologous HSCs. Increasing Hgb and WBC count, younger age, and history of splenectomy were associated with improved CD34/kg collected. These findings may inform the development of standardized data-driven approaches to transfusion preparation and stem cell mobilization, ultimately improving access to gene therapy for patients with SCD.

Mauricio Barreto, MD: No relevant conflicts of interest to declare.